Patent Exhaustion Doctrine

Patent exhaustion — also called the first-sale doctrine for patents — is the principle that once a patent owner (or someone authorized by the patent owner) sells a patented item, the patent owner’s exclusive rights over that specific item are used up, or “exhausted.” The purchaser, and anyone who later buys or uses that same item, is free to use, repair, or resell it without committing patent infringement, even though the underlying patent is still valid and enforceable against unauthorized new copies of the invention.

Exhaustion is triggered by an authorized sale of a physical, patented article. It does not invalidate the patent itself, and it does not give the purchaser any right to make additional copies of the invention — only to use, repair, or resell the particular item that was sold.

The Impression Products v. Lexmark ruling

The U.S. Supreme Court’s controlling decision on this doctrine is Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 360 (2017). Lexmark sold printer toner cartridges under a program that restricted purchasers to single use and prohibited resale; a third party, Impression Products, refurbished and resold used Lexmark cartridges anyway, and Lexmark sued for patent infringement. The Court held for Impression Products on two points that now define the doctrine:

• Post-sale restrictions don’t survive as patent claims. An authorized sale exhausts all patent rights in that item regardless of any restriction the patentee tries to impose on the buyer at the point of sale. A patentee can still try to enforce a restriction as an ordinary contract term against the party who agreed to it, but it can no longer sue a downstream purchaser or user for patent infringement over that restriction.
• Exhaustion applies to authorized foreign sales too. The Court rejected the prior Federal Circuit rule that only U.S. sales exhausted U.S. patent rights, holding that an authorized sale anywhere in the world exhausts the patentee’s U.S. patent rights in that item.

The ruling was unanimous on the domestic-exhaustion question; Justice Ginsburg dissented in part on the international-exhaustion holding. Lexmark reaffirmed and extended a line of exhaustion cases going back to 19th-century Supreme Court precedent (Bloomer v. McQuewan, Adams v. Burke) rather than creating the doctrine from nothing — its significance is in foreclosing two specific workarounds patent owners had been using: notice-based post-sale restrictions and a U.S.-sales-only reading of exhaustion.

What exhaustion does not reach

Exhaustion is narrower than it’s sometimes assumed to be. It does not apply to:

• Unauthorized sales. If a sale falls outside the scope of what the patent owner actually authorized — for example, a licensee sells outside a field-of-use restriction that limits what the license itself covers — that sale is not “authorized,” exhaustion does not attach, and the patent owner can still bring an infringement claim.
• Making new copies. A purchaser who owns a lawfully sold patented item cannot use exhaustion as a defense for manufacturing new units of the same invention; exhaustion covers use, repair, and resale of the specific article sold, not reconstruction of it.
• Pure licenses with no sale. Exhaustion is a doctrine about sales of physical articles, not about licenses generally — a license that only grants rights to practice a patent, without an authorized sale of a tangible item ever occurring, doesn’t trigger the same analysis.

Why this matters in university technology transfer

Exhaustion is directly relevant whenever a technology transfer office licenses a patented research tool, reagent, instrument, or other tangible embodiment of an invention rather than the underlying know-how alone. Two distinctions matter in practice:

• Restrictions on the licensee’s own scope of authority survive as patent-scope questions. A patent owner can license a manufacturer to make and sell a patented product only within a defined field of use, territory, or quantity. A sale that falls outside that authorized scope is an unauthorized sale — the licensee itself can be liable for infringement, and exhaustion never attaches to that sale in the first place. This is the mechanism behind field-of-use-restricted patent licensing deals TTOs commonly negotiate (e.g., a research-tool patent licensed for commercial diagnostic use but reserved for the university’s own non-commercial research use).
• Restrictions on what a downstream buyer does with a properly authorized sale do not survive as patent claims. Once a sale is authorized and within the licensed scope, Lexmark means the licensee (and the university, as the underlying patent owner) cannot use patent infringement law to police what the buyer does afterward — labeling a research reagent “single use” or “not for resale” does not give rise to a patent infringement claim against a lab that reuses or resells it. Any such restriction has to be enforced, if at all, as an ordinary contract term against the party who actually agreed to it, which is one reason material transfer agreements for research materials are usually structured as contracts with their own use restrictions and remedies, rather than relying on patent rights to control downstream use.

Getting the field-of-use/license-scope distinction right at the drafting stage is what determines whether a downstream restriction is enforceable at all — a restriction embedded in the license’s authorized scope (so an out-of-scope sale is unauthorized) behaves very differently, after Lexmark, from the same restriction imposed only as a condition on the buyer after an otherwise-authorized sale.

Patent exhaustion vs. copyright’s first-sale doctrine

Patent exhaustion is often discussed alongside copyright’s own first-sale doctrine (17 U.S.C. § 109, addressed for copyrighted works by the Supreme Court in Kirtsaeng v. John Wiley & Sons, 568 U.S. 519 (2013)). Both share the same underlying logic — an authorized sale exhausts the IP owner’s distribution-related rights in that specific copy — but they are separate doctrines under separate statutes, and a single product (packaged software, for instance) can implicate both a patent exhaustion analysis and a copyright first-sale analysis at once.

Frequently asked questions

Does patent exhaustion apply to licenses, or only to sales?

Exhaustion is triggered specifically by an authorized sale of a patented article. A license by itself, without an authorized sale of a tangible item, does not trigger exhaustion in the same way — though a sale made pursuant to an authorized license is exactly the kind of sale that does trigger it.

Can a patent owner still enforce a “no resale” label after Impression Products v. Lexmark?

Not through a patent infringement suit. The label can still function as a contract term enforceable against whoever agreed to it, but it can no longer be enforced against downstream purchasers as a matter of patent law.

Does exhaustion apply if the original sale happened outside the United States?

Yes. Impression Products v. Lexmark held that an authorized sale anywhere in the world exhausts the patentee’s U.S. patent rights in that item, overruling the prior rule that only domestic sales triggered exhaustion.

Related terms

• Utility Patent
• Patent Prosecution
• Non-Practicing Entity (NPE)
• Material Transfer Agreement (MTA)
• Bayh-Dole Act
• Patent Licensing (guide)